GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharos IBio Co Ltd (XKRX:388870) » Definitions » Debt-to-EBITDA

Pharos IBio Co (XKRX:388870) Debt-to-EBITDA : -0.02 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Pharos IBio Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pharos IBio Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩154.81 Mil. Pharos IBio Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₩84.60 Mil. Pharos IBio Co's annualized EBITDA for the quarter that ended in Mar. 2024 was ₩-11,235.04 Mil. Pharos IBio Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was -0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Pharos IBio Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:388870' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.21   Med: -0.04   Max: -0.02
Current: -0.03

During the past 5 years, the highest Debt-to-EBITDA Ratio of Pharos IBio Co was -0.02. The lowest was -0.21. And the median was -0.04.

XKRX:388870's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.31 vs XKRX:388870: -0.03

Pharos IBio Co Debt-to-EBITDA Historical Data

The historical data trend for Pharos IBio Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharos IBio Co Debt-to-EBITDA Chart

Pharos IBio Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.21 -0.07 -0.02 -0.03 -0.04

Pharos IBio Co Quarterly Data
Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial -0.03 -0.04 -0.04 -0.04 -0.02

Competitive Comparison of Pharos IBio Co's Debt-to-EBITDA

For the Biotechnology subindustry, Pharos IBio Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharos IBio Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharos IBio Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pharos IBio Co's Debt-to-EBITDA falls into.



Pharos IBio Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Pharos IBio Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(177.249 + 127.703) / -8162.216
=-0.04

Pharos IBio Co's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(154.806 + 84.602) / -11235.044
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Pharos IBio Co  (XKRX:388870) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Pharos IBio Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pharos IBio Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharos IBio Co (XKRX:388870) Business Description

Traded in Other Exchanges
N/A
Address
427beon-gil, Dongan-gu, 1407 and 1408, 38, Heungan-daero, Seongji Star With, Gyeonggi-do, Gwanyang-dong, Anyang-si, KOR
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.

Pharos IBio Co (XKRX:388870) Headlines

No Headlines